EP4687820A1 - Microbiome friendly substances and microbiome friendly cosmetic formulations - Google Patents

Microbiome friendly substances and microbiome friendly cosmetic formulations

Info

Publication number
EP4687820A1
EP4687820A1 EP24715127.7A EP24715127A EP4687820A1 EP 4687820 A1 EP4687820 A1 EP 4687820A1 EP 24715127 A EP24715127 A EP 24715127A EP 4687820 A1 EP4687820 A1 EP 4687820A1
Authority
EP
European Patent Office
Prior art keywords
formulation
cetearyl
microbiome
sodium
polyglyceryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24715127.7A
Other languages
German (de)
French (fr)
Inventor
Annette Mehling
Qiu Jing WANG
Xiao Yue WANG
Qiao Ming ZHANG
Han Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP4687820A1 publication Critical patent/EP4687820A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers

Definitions

  • the present invention relates to the use of specific substances as microbiome friendly ingredients in a cosmetic formulation. It furthermore relates to cosmetic formulations having a composition which are microbiome friendly.
  • the present invention relates to the use of formulation ingredients (galenics, e.g. emulsifiers, emollients, rheology modifiers) that do not significantly alter the natural composition of the skin and/or scalp and/or mucous membrane microbial communities and with it the specific microbiomes.
  • formulation ingredients galenics, e.g. emulsifiers, emollients, rheology modifiers
  • the following definition of the skin microbiome essentially refers to a report of the International Cooperation on Cosmetics Regulation dated June 28 th , 2022.
  • the skin microbiome is present on the whole skin surface, including oral cavity and mucosal surfaces of the external genital organs.
  • the composition of the skin microbiome is dynamic, site-specific but also differs from individual to individual.
  • the skin microbiome includes also microorganisms found on e.g., the scalp, pilosebaceous follicles or sebaceous glands. It also comprises microorganisms detected in the epidermis or dermis.
  • microbiota and “microbiome” are not synonymous as the microbiota only refers to the microorganisms, whereas the microbiome also includes their functional potential. These two terms are mainly used in the scientific literature, whereas in the public domain both terms are often used interchangeably.
  • the microbiome is a characteristic microbial community occupying a reasonably well-defined habitat which has distinct physio-chemical properties.
  • the microbiome not only refers to the microorganisms involved but also encompasses their theatre of activity, which results in the formation of specific ecological niches. This includes their genetic material, and also structural molecules, like enzymes, membrane lipids or polysaccharides.
  • microbiome research is one that has made major strides in the past years. Historically, the microorganisms found on or in the human body were generally viewed as being pathogens and as such deleterious to human health. With the introduction of new methodologies, this has proven to be a misconception. The microbial communities on and in our bodies have been found to contribute to our health. The microbes inhabiting e.g. our skin interact both with each other and with their hosts.
  • Staphylococcus epidermis can produce modulins that can hinder the growth of some pathogens; Cutibacterium (formerly Propionibacterium) acnes can degrade triglycerides found in sebum, which in turn sets free fatty acids needed to maintain the natural skin pH and the skin barrier. This further augment the natural immunity of the skin by both inhibiting growth of certain bacteria and by e.g. stimulating the expression of beta defensin 2 by the skin. This intricate interplay is further influenced by various factors, e.g. gender, age, body location, individual susceptibility and the environment.
  • the composition e.g. of the skin’s microbiota is adapted to its host and environment. Dysbiosis can lead to skin damage and is associated with skin conditions, such as atopic dermatitis where the pathogen Staphylococcus aureus is involved.
  • US 2008/0070986 discloses the use of alkyl ether citrates for protecting and maintaining the natural skin/mucous membrane microflora and the microbial skin/mucous membrane ecosystem without impairing the natural balancing processes which limit the number of pathogenic bacteria so that they do not become disease-inducing.
  • Specchemonline.com Nov/Dec 2021 , pages 24-26 disclose microbiome-friendly formulation chassis. Single cosmetic ingredients as well as formulations have been tested in vitro (MIC- tests; MIC: minimal inhibitory concentration) and in vivo.
  • EP 3 970 802 discloses a skin care composition for promoting the skin microbiome comprising (a) pyruvate and/or lactate in combination with either (b1) urea and/or arginine, or with (b2) caprylic/capric triglycerides, or with (b1) and (b2).
  • the problem underlying the present invention is to provide ingredients for cosmetic formulations that avoid significantly changing the healthy microbial communities and microbiomes. Such ingredients are hereinafter called microbiome friendly. Formulations which, as a whole, avoid significantly changing the healthy microbial communities and microbiomes are also called microbiome friendly. If the said ingredients are, as such, known in the state of the art, but their use as a microbiome friendly ingredient in a cosmetic formulation is not known in the state of the art, then the solution of the problem underlying the present invention is this use.
  • microbiome friendliness is determined via MIC values, then the MIC value determined for the microorganism Staphylococcus epidermidis when tested in the vehicle ethanol/water (1 :1) is especially relevant.
  • the solutions to the problem underlying the present invention, and a first subject of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Laureth-7 Citrate,
  • One embodiment of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is an emulsifier.
  • This means that one embodiment of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassi
  • a preferred embodiment of the first subject of the present invention is obtained, when the use according to the previous paragraph is restricted to emulsifiers having a MIC value of not below 1.
  • the relevance of the MIC value is explained in the experimental section of the present document.
  • a MIC value of not below 1 essentially means that the substances having such a high MIC value have an especially favorable effect on the microbiome.
  • a preferred embodiment of the first subject of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate and Potassium Cetyl Phosphate.
  • this substance is selected from the group consisting of Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, ethyl linoleate, Glyceryl Oleate,
  • a more preferred embodiment is obtained, when the use is restricted to emulsifiers having a MIC value of not below 3.
  • a more preferred embodiment of the first subject of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Glyceryl Stearate Citrate and Lecithin.
  • the use described in the previous paragraphs is a non-therapeutic use.
  • a second subject of the present invention corresponds to the use as described in the previous paragraphs. It is a method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with a substance as defined in the previous paragraphs.
  • a second subject of the present invention is a method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with a substance selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin
  • Preferred embodiments of the method described in the previous paragraph are methods related to selected substances corresponding to the preferred uses described in this document.
  • a third subject of the present invention is a substance for use in a method for treatment of the human or animal body by therapy, including prophylaxis, wherein this substance is selected from the group consisting of Ceteareth-12, Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Glycerin, Dehydroacetic Acid (and) Benzy
  • a fourth subject of the present invention is a substance for use in a method for treating or preventing a disease caused by a disorder of the skin microbiome, wherein this substance is selected from the group consisting of Ceteareth-12, Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Glycerin, Dehydroacetic Acid (and)
  • a fifth subject of the present invention is a cosmetic formulation having a composition identical to the composition of any of the following formulations or having a composition deviating from the composition of the following formulations in such a way that the amounts of the components of the cosmetic formulation deviate from the amounts of the components of the following formulations by +- 20 %, preferably +- 10 %, more preferably by +- 5 %,
  • a further embodiment of the present invention is the non-therapeutic, cosmetic use of any of the formulations 1 to 9 as a microbiome friendly cosmetic formulation.
  • a further embodiment of the present invention is a method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with any of the formulations 1 to 9.
  • a further embodiment of the present invention is a formulation, selected from the group consisting of formulations 1 to 9, for use in a method for treatment of the human or animal body by therapy, including prophylaxis.
  • a further embodiment of the present invention is a formulation, selected from the group consisting of formulations 1 to 9, for use in a method for treating or preventing a disease caused by a disorder of the skin microbiome.
  • the main intent was to identify ingredients that do not disrupt the complex microbial communities found on healthy skin.
  • a selection of ingredients was screened using minimal inhibitory concentration tests (MICs) and/or using 16S rDNA/rRNA microbiome analyses of skin swabs taken before and after 28 days of use by human volunteers with healthy skin (in vivo). Based on the results, skin care formulations were developed and tested in vivo as proof-of-concept studies.
  • composition deviating from the composition of a given formulation in such a way that the amounts of the components of the composition deviate from the amounts of the components of the given formulation by +-10 % means that, based on a given formulation having, e. g., 5 % by weight Glycerin and 10 % Butylene Glycol, any composition having 4.5 to 5.5 % by weight Glycerin and 9 to 11 % by weight Butylene Glycol is a composition according to the definition given by the said expression.
  • % means % by weight unless defined differently.
  • Hydrophilic ingredients including emulsifiers and rheology modifiers were evaluated using minimal inhibitory concentration tests (MIC tests). Lipophilic substances, including emollients, and formulations were tested on the skin of human volunteers (in vivo tests).
  • Minimal Inhibitory Concentration tests are tests typically used to measure growth inhibition by a substance. MICs are defined as the lowest test concentrations of the test substance at which growth of specific microorganisms are inhibited.
  • test concentrations are given as percent of active substance content.
  • Primers targeting variable regions of bacterial 16S rDNA/rRNA were used to amplify the genetic material obtained during swabbing via polymerase chain reaction (PCR) techniques. Following sequencing, the sequences were clustered into operational taxonomic units (OTUs) a 97 % similarity threshold defining taxonomic levels, e.g. phyla and genus. Biodiversity was determined using alpha diversity as a measure of microbial richness and abundance and calculating the Shannon diversity index. Wilcoxon signed-rank tests were used to determine statistical significance.
  • OTUs operational taxonomic units
  • results of MIC test (MIC in % by weight) These results are to be interpreted as follows. For each substance the lowest MIC value obtained determines whether this substance in useful as microbiome friendly cosmetic ingredient. A substance is useful as microbiome friendly cosmetic ingredient, if this lowest MIC is not lower than a threshold value. This threshold value depends on the type of the substance (solubilizer, emulsifier etc.) and is related to the amount in which these types of substances are generally used in common cosmetic formulations.
  • the lowest MIC should not be below 0.05 %, preferably not below 0.08 %, more preferably not below 0.5 %, more preferably not below 1 %, more preferably not below 2 %, more preferably not below 3 %.
  • the lowest MIC should not be below 0.1 %, preferably not below 0.25 %, preferably not below 0.5 %, preferably not below 1 %, preferably not below 2 %.
  • the lowest MIC should not be below 0.25 %, preferably not below 0.5 %, more preferably not below 1 %, more preferably not below 2 %..
  • the lowest MIC should not be below 0.1 %, preferably not below 0.25 %, preferably not below 0.5 %, preferably not below 1 %, preferably not below 2 %.
  • the lowest MIC should not be below 1 %, preferably not below 2 %, more preferably not below 20 %.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to the use of specific substances as microbiome friendly ingredients in a cosmetic formulation. It furthermore relates to cosmetic formulations having a composition which are microbiome friendly.

Description

Microbiome friendly substances and microbiome friendly cosmetic formulations
The present invention relates to the use of specific substances as microbiome friendly ingredients in a cosmetic formulation. It furthermore relates to cosmetic formulations having a composition which are microbiome friendly.
The present invention relates to the use of formulation ingredients (galenics, e.g. emulsifiers, emollients, rheology modifiers) that do not significantly alter the natural composition of the skin and/or scalp and/or mucous membrane microbial communities and with it the specific microbiomes. As the composition of the microbial communities are adapted to the host and its environment, it plays an essential role in the natural balancing processes which limit growth of pathogens and needed to help maintain the host’s health.
The following definition of the skin microbiome essentially refers to a report of the International Cooperation on Cosmetics Regulation dated June 28th, 2022. The skin microbiome is present on the whole skin surface, including oral cavity and mucosal surfaces of the external genital organs. The composition of the skin microbiome is dynamic, site-specific but also differs from individual to individual. The skin microbiome includes also microorganisms found on e.g., the scalp, pilosebaceous follicles or sebaceous glands. It also comprises microorganisms detected in the epidermis or dermis. It should be noted that the two terms “microbiota” and “microbiome” are not synonymous as the microbiota only refers to the microorganisms, whereas the microbiome also includes their functional potential. These two terms are mainly used in the scientific literature, whereas in the public domain both terms are often used interchangeably.
The microbiome is a characteristic microbial community occupying a reasonably well-defined habitat which has distinct physio-chemical properties. The microbiome not only refers to the microorganisms involved but also encompasses their theatre of activity, which results in the formation of specific ecological niches. This includes their genetic material, and also structural molecules, like enzymes, membrane lipids or polysaccharides.
The field of microbiome research is one that has made major strides in the past years. Historically, the microorganisms found on or in the human body were generally viewed as being pathogens and as such deleterious to human health. With the introduction of new methodologies, this has proven to be a misconception. The microbial communities on and in our bodies have been found to contribute to our health. The microbes inhabiting e.g. our skin interact both with each other and with their hosts. On the human skin, Staphylococcus epidermis can produce modulins that can hinder the growth of some pathogens; Cutibacterium (formerly Propionibacterium) acnes can degrade triglycerides found in sebum, which in turn sets free fatty acids needed to maintain the natural skin pH and the skin barrier. This further augment the natural immunity of the skin by both inhibiting growth of certain bacteria and by e.g. stimulating the expression of beta defensin 2 by the skin. This intricate interplay is further influenced by various factors, e.g. gender, age, body location, individual susceptibility and the environment. The composition e.g. of the skin’s microbiota is adapted to its host and environment. Dysbiosis can lead to skin damage and is associated with skin conditions, such as atopic dermatitis where the pathogen Staphylococcus aureus is involved.
The effects of topical applications on the e.g. the skin’s microbiota are increasingly being explored. The use of topically applied substances has the potential of affecting the microbial communities, which in turn can lead to dysbiosis. Currently, the focus is on how bioactives, such as pre-, pro- or postbiotics, can change the microbial composition of the skin. Yet, it is also clear that the healthy balance of the natural microbial inhabitants is also of the essence.
US 2008/0070986 discloses the use of alkyl ether citrates for protecting and maintaining the natural skin/mucous membrane microflora and the microbial skin/mucous membrane ecosystem without impairing the natural balancing processes which limit the number of pathogenic bacteria so that they do not become disease-inducing.
Specchemonline.com, Nov/Dec 2021 , pages 24-26 disclose microbiome-friendly formulation chassis. Single cosmetic ingredients as well as formulations have been tested in vitro (MIC- tests; MIC: minimal inhibitory concentration) and in vivo.
EP 3 970 802 discloses a skin care composition for promoting the skin microbiome comprising (a) pyruvate and/or lactate in combination with either (b1) urea and/or arginine, or with (b2) caprylic/capric triglycerides, or with (b1) and (b2).
The problem underlying the present invention is to provide ingredients for cosmetic formulations that avoid significantly changing the healthy microbial communities and microbiomes. Such ingredients are hereinafter called microbiome friendly. Formulations which, as a whole, avoid significantly changing the healthy microbial communities and microbiomes are also called microbiome friendly. If the said ingredients are, as such, known in the state of the art, but their use as a microbiome friendly ingredient in a cosmetic formulation is not known in the state of the art, then the solution of the problem underlying the present invention is this use.
If microbiome friendliness is determined via MIC values, then the MIC value determined for the microorganism Staphylococcus epidermidis when tested in the vehicle ethanol/water (1 :1) is especially relevant.
Therefore, the solutions to the problem underlying the present invention, and a first subject of the present invention, is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Laureth-7 Citrate, Glycerin, Dehydroacetic Acid (and) Benzyl Alcohol, Glycerin (and) Aqua (and) Sodium Levulinate (and) Sodium Anisate, Phenoxyethanol (and) Ethylhexylglycerin, Phenoxyethanol (and) Hydroxyacetophenone (and) Caprylyl Glycol (and) Water, Sodium Benzoate, Acrylates/Beheneth-25 Methacrylate Copolymer, Alginate, Caesalpinia Spinosa Gum, Glucomannan, Sodium Polyacrylate, Xanthan Gum, 1 ,4 Butandiol, Butylene Glycol, polyethylene glycol, Triethyl Citrate, Conjugated Linoleic Acid, Vegetable Oil, Passiflora Incarnata Seed Oil, Dicaprylyl Carbonate, Isononyl Isononanoate, Coco-Caprylate/Caprate, Dicaprylyl Ether, Caprylyl Caprylate/Caprate, Butyrospermum Parkii (Shea) Butter, Propylheptyl Caprylate, Undecane (and) Tridecane, Citric Acid, Hydrogenated Vegetable Glycerides, Sucrose Polystearate (and) Cetyl Palmitate, Sodium Stearoyl Glutamate, Octyldodecanol, Phenoxyethanol (and) Methylparaben, Polyglyceryl-3 Diisostearate, Cetearyl Alcohol, Ethylparaben (and) Propylene Glycol, Dipropylheptyl Carbonate, Glycerin (and) Myristyl Myristate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Cetearyl Alcohol (and) Potassium Cetyl Phosphate, Glycerin (and) Cetyl Palmitate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Pentylene Glycol (and) Sodium Stearoyl Glutamate (and) Ceteareth-20 (and) Tetrahydroxypropyl Ethylenediamine (and) Cetearyl Alcohol (and) Water, Cetyl Ethylhexanoate, Ethylhexyl Palmitate, Triethylhexanoin, Cocoglycerides, Polyglyceryl-10 stearate, Polyglyceryl-10 Oleate, and Cetearyl Glucoside (and) Cetearyl Alcohol.
One embodiment of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is an emulsifier. This means that one embodiment of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Laureth-7 Citrate, Polyglyceryl-10 stearate, Polyglyceryl-10 Oleate, and Cetearyl Glucoside (and) Cetearyl Alcohol.
A preferred embodiment of the first subject of the present invention is obtained, when the use according to the previous paragraph is restricted to emulsifiers having a MIC value of not below 1. The relevance of the MIC value is explained in the experimental section of the present document. A MIC value of not below 1 essentially means that the substances having such a high MIC value have an especially favorable effect on the microbiome.
Therefore, a preferred embodiment of the first subject of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate and Potassium Cetyl Phosphate.
A more preferred embodiment is obtained, when the use is restricted to emulsifiers having a MIC value of not below 3.
Therefore, a more preferred embodiment of the first subject of the present invention is the use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Glyceryl Stearate Citrate and Lecithin.
Preferably, the use described in the previous paragraphs is a non-therapeutic use.
A second subject of the present invention corresponds to the use as described in the previous paragraphs. It is a method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with a substance as defined in the previous paragraphs. I. e., a second subject of the present invention is a method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with a substance selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Glycerin, Dehydroacetic Acid (and) Benzyl Alcohol, Glycerin (and) Aqua (and) Sodium Levulinate (and) Sodium Anisate, Phenoxyethanol (and) Ethylhexylglycerin, Phenoxyethanol (and) Hydroxyacetophenone (and) Caprylyl Glycol (and) Water, Sodium Benzoate, Acrylates/Beheneth-25 Methacrylate Copolymer, Alginate, Caesalpinia Spinosa Gum, Glucomannan, Sodium Polyacrylate, Xanthan Gum, 1 ,4 Butandiol, Butylene Glycol, polyethylene glycol, Triethyl Citrate, Laureth-7 Citrate, Conjugated Linoleic Acid, Vegetable Oil, Passiflora Incarnata Seed Oil, Dicaprylyl Carbonate, Isononyl Isononanoate, Coco- Caprylate/Caprate, Dicaprylyl Ether, Caprylyl Caprylate/Caprate, Butyrospermum Parkii (Shea) Butter, Propylheptyl Caprylate, Undecane (and) Tridecane, Citric Acid, Hydrogenated Vegetable Glycerides, Sucrose Polystearate (and) Cetyl Palmitate, Sodium Stearoyl Glutamate, Octyldodecanol, Phenoxyethanol (and) Methylparaben, Polyglyceryl-3 Diisostearate, Cetearyl Alcohol, Ethylparaben (and) Propylene Glycol, Dipropylheptyl Carbonate, Glycerin (and) Myristyl Myristate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Cetearyl Alcohol (and) Potassium Cetyl Phosphate, Glycerin (and) Cetyl Palmitate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Pentylene Glycol (and) Sodium Stearoyl Glutamate (and) Ceteareth-20 (and) Tetrahydroxypropyl Ethylenediamine (and) Cetearyl Alcohol (and) Water, Cetyl Ethylhexanoate, Ethylhexyl Palmitate, Triethylhexanoin, Cocoglycerides, Polyglyceryl-10 stearate, Polyglyceryl-10 Oleate, and Cetearyl Glucoside (and) Cetearyl Alcohol.
Preferred embodiments of the method described in the previous paragraph are methods related to selected substances corresponding to the preferred uses described in this document.
A third subject of the present invention is a substance for use in a method for treatment of the human or animal body by therapy, including prophylaxis, wherein this substance is selected from the group consisting of Ceteareth-12, Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Glycerin, Dehydroacetic Acid (and) Benzyl Alcohol, Glycerin (and) Aqua (and) Sodium Levulinate (and) Sodium Anisate, Phenoxyethanol (and) Ethylhexylglycerin, Phenoxyethanol (and) Hydroxyacetophenone (and) Caprylyl Glycol (and) Water, Sodium Benzoate, Acrylates/Beheneth-25 Methacrylate Copolymer, Alginate, Caesalpinia Spinosa Gum, Glucomannan, Sodium Polyacrylate, Xanthan Gum, 1 ,4 Butandiol, Butylene Glycol, polyethylene glycol, Triethyl Citrate, Laureth-7 Citrate, Conjugated Linoleic Acid, Vegetable Oil, Passiflora Incarnata Seed Oil, Dicaprylyl Carbonate, Isononyl Isononanoate, Coco- Caprylate/Caprate, Dicaprylyl Ether, Caprylyl Caprylate/Caprate, Butyrospermum Parkii (Shea) Butter, Propylheptyl Caprylate, Undecane (and) Tridecane, Citric Acid, Hydrogenated Vegetable Glycerides, Sucrose Polystearate (and) Cetyl Palmitate, Sodium Stearoyl Glutamate, Octyldodecanol, Phenoxyethanol (and) Methylparaben, Polyglyceryl-3 Diisostearate, Cetearyl Alcohol, Ethylparaben (and) Propylene Glycol, Dipropylheptyl Carbonate, Glycerin (and) Myristyl Myristate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Cetearyl Alcohol (and) Potassium Cetyl Phosphate, Glycerin (and) Cetyl Palmitate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Pentylene Glycol (and) Sodium Stearoyl Glutamate (and) Ceteareth-20 (and) Tetrahydroxypropyl Ethylenediamine (and) Cetearyl Alcohol (and) Water, Cetyl Ethylhexanoate, Ethylhexyl Palmitate, Triethylhexanoin, Cocoglycerides, Polyglyceryl-10 stearate, Polyglyceryl-10 Oleate, and Cetearyl Glucoside (and) Cetearyl Alcohol.
A fourth subject of the present invention is a substance for use in a method for treating or preventing a disease caused by a disorder of the skin microbiome, wherein this substance is selected from the group consisting of Ceteareth-12, Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Glycerin, Dehydroacetic Acid (and) Benzyl Alcohol, Glycerin (and) Aqua (and) Sodium Levulinate (and) Sodium Anisate, Phenoxyethanol (and) Ethylhexylglycerin, Phenoxyethanol (and) Hydroxyacetophenone (and) Caprylyl Glycol (and) Water, Sodium Benzoate, Acrylates/Beheneth-25 Methacrylate Copolymer, Alginate, Caesalpinia Spinosa Gum, Glucomannan, Sodium Polyacrylate, Xanthan Gum, 1 ,4 Butandiol, Butylene Glycol, polyethylene glycol, Triethyl Citrate, Laureth-7 Citrate, Conjugated Linoleic Acid, Vegetable Oil, Passiflora Incarnata Seed Oil, Dicaprylyl Carbonate, Isononyl Isononanoate, Coco-Caprylate/Caprate, Dicaprylyl Ether, Caprylyl Caprylate/Caprate, Butyrospermum Parkii (Shea) Butter, Propylheptyl Caprylate, Undecane (and) Tridecane, Citric Acid, Hydrogenated Vegetable Glycerides, Sucrose Polystearate (and) Cetyl Palmitate, Sodium Stearoyl Glutamate, Octyldodecanol, Phenoxyethanol (and) Methyl paraben, Polyglyceryl-3 Di isostearate, Cetearyl Alcohol, Ethylparaben (and) Propylene Glycol, Dipropylheptyl Carbonate, Glycerin (and) Myristyl Myristate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Cetearyl Alcohol (and) Potassium Cetyl Phosphate, Glycerin (and) Cetyl Palmitate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Pentylene Glycol (and) Sodium Stearoyl Glutamate (and) Ceteareth-20 (and) Tetrahydroxypropyl Ethylenediamine (and) Cetearyl Alcohol (and) Water, Cetyl Ethylhexanoate, Ethylhexyl Palmitate, Triethylhexanoin, Cocoglycerides, Polyglyceryl-10 stearate, Polyglyceryl-10 Oleate, and Cetearyl Glucoside (and) Cetearyl Alcohol.
A fifth subject of the present invention is a cosmetic formulation having a composition identical to the composition of any of the following formulations or having a composition deviating from the composition of the following formulations in such a way that the amounts of the components of the cosmetic formulation deviate from the amounts of the components of the following formulations by +- 20 %, preferably +- 10 %, more preferably by +- 5 %,
Formulation 1 :
Formulation 2:
Formulation 3: Formulation 4:
Formulation 5:
Formulation 6:
Formulation 7: Formulation 8:
Formulation 9:
A further embodiment of the present invention is the non-therapeutic, cosmetic use of any of the formulations 1 to 9 as a microbiome friendly cosmetic formulation.
A further embodiment of the present invention is a method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with any of the formulations 1 to 9.
A further embodiment of the present invention is a formulation, selected from the group consisting of formulations 1 to 9, for use in a method for treatment of the human or animal body by therapy, including prophylaxis.
A further embodiment of the present invention is a formulation, selected from the group consisting of formulations 1 to 9, for use in a method for treating or preventing a disease caused by a disorder of the skin microbiome. As the composition of the healthy skin microbiota varies between individuals, the main intent was to identify ingredients that do not disrupt the complex microbial communities found on healthy skin. A selection of ingredients was screened using minimal inhibitory concentration tests (MICs) and/or using 16S rDNA/rRNA microbiome analyses of skin swabs taken before and after 28 days of use by human volunteers with healthy skin (in vivo). Based on the results, skin care formulations were developed and tested in vivo as proof-of-concept studies.
Significantly changing the healthy microbial communities and microbiomes can have several negative consequences. Some of these consequences are merely of cosmetic nature, e. g. red skin, dry skin or the like. Avoiding these consequences therefore is a cosmetic activity and is not therapy or prophylaxis in a medical sense. Other consequences can be pathological and can result in diseases caused by a disorder of the skin microbiome.
The expression “a composition deviating from the composition of a given formulation in such a way that the amounts of the components of the composition deviate from the amounts of the components of the given formulation by +-10 %” means that, based on a given formulation having, e. g., 5 % by weight Glycerin and 10 % Butylene Glycol, any composition having 4.5 to 5.5 % by weight Glycerin and 9 to 11 % by weight Butylene Glycol is a composition according to the definition given by the said expression.
Examples
% means % by weight unless defined differently.
Test Methods
Hydrophilic ingredients, including emulsifiers and rheology modifiers were evaluated using minimal inhibitory concentration tests (MIC tests). Lipophilic substances, including emollients, and formulations were tested on the skin of human volunteers (in vivo tests).
Minimal inhibitory concentration tests (MICs)
Minimal Inhibitory Concentration tests are tests typically used to measure growth inhibition by a substance. MICs are defined as the lowest test concentrations of the test substance at which growth of specific microorganisms are inhibited.
In the present case predefined dilutions of the test substance in the appropriate culture medium were prepared and inoculated with the microorganism of interest. After incubation, the test organisms were cultured over a time-period and under conditions normally allowing growth of the microorganism. Vehicle controls (vehicle = solvent used, e. g. water) were also assessed to determine growth without the test substance. The organisms of interest tested were the representative strains S. aureus (found on the skin, often a pathogen), S. epidermidis and Malassezia furfur. The higher the MIC value, the less inhibition of growth is observed. In the following results the test concentrations are given as percent of active substance content.
In vivo tests on human skin
In vivo studies were conducted. The general procedure was as follows. At least 20 volunteers having given informed consent and presenting with healthy skin were asked to apply the test sample to the volar forearm twice daily for 28 days. Volunteers were asked to refrain from using topical products 7 days prior to the start and throughout the study. Each test sample was applied randomized to one of four predefined tests area. An untreated area served as a reference. The skin was treated under standardized conditions. The area of interest was swabbed prior to sample application and after 28 days of use. The swabs were stored on dry ice until subjected to genetic analyses.
Genetic analyses
Primers targeting variable regions of bacterial 16S rDNA/rRNA were used to amplify the genetic material obtained during swabbing via polymerase chain reaction (PCR) techniques. Following sequencing, the sequences were clustered into operational taxonomic units (OTUs) a 97 % similarity threshold defining taxonomic levels, e.g. phyla and genus. Biodiversity was determined using alpha diversity as a measure of microbial richness and abundance and calculating the Shannon diversity index. Wilcoxon signed-rank tests were used to determine statistical significance.
Results of MIC test (MIC in % by weight) These results are to be interpreted as follows. For each substance the lowest MIC value obtained determines whether this substance in useful as microbiome friendly cosmetic ingredient. A substance is useful as microbiome friendly cosmetic ingredient, if this lowest MIC is not lower than a threshold value. This threshold value depends on the type of the substance (solubilizer, emulsifier etc.) and is related to the amount in which these types of substances are generally used in common cosmetic formulations.
For emulsifiers the lowest MIC should not be below 0.05 %, preferably not below 0.08 %, more preferably not below 0.5 %, more preferably not below 1 %, more preferably not below 2 %, more preferably not below 3 %.
For humectants the lowest MIC should not be below 0.1 %, preferably not below 0.25 %, preferably not below 0.5 %, preferably not below 1 %, preferably not below 2 %.
For preservatives the lowest MIC should not be below 0.25 %, preferably not below 0.5 %, more preferably not below 1 %, more preferably not below 2 %..
For rheology modifiers the lowest MIC should not be below 0.1 %, preferably not below 0.25 %, preferably not below 0.5 %, preferably not below 1 %, preferably not below 2 %.
For solubilizers the lowest MIC should not be below 1 %, preferably not below 2 %, more preferably not below 20 %.
For conjugated linoleic acid the lowest MIC should not be below 1 %.
Results of genetic analyses / in vivo tests
In vivo tests were carried out with the formulations listed in the following table. Each formulation and the ingredients they contain, was found to be useful as microbiome friendly formulations as well as ingredients. Therefore, any ingredient of the formulations tested can be included in the list of ingredients present in patent claims 1 , 3, 4 and 5 of the present patent application as filed.
Formulations
The following formulations were used for the genetic analyses I in vivo tests.
Formulation no. SC-DE-20-089-1
Formulation no. SC-DE-20-044-2
Formulation no. SC-DE-20-067-8 Formulation no. SC-CN-22-VZ011302
Formulation no. SC-SC-22-VZ011102
Formulation no. SC-CN-22-VZ021001 Formulation no. SC-CN-22-VZ092002
Formulation no. SC-CN-22-WL092002
Formulation no. SC-CN-22-VZ101901

Claims

Claims
1. The use of a substance as a microbiome friendly ingredient in a cosmetic formulation, wherein this substance is selected from the group consisting of Ceteareth-12,Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate, Laureth-7 Citrate, Glycerin, Dehydroacetic Acid (and) Benzyl Alcohol, Glycerin (and) Aqua (and) Sodium Levulinate (and) Sodium Anisate, Phenoxyethanol (and) Ethylhexylglycerin, Phenoxyethanol (and) Hydroxyacetophenone (and) Caprylyl Glycol (and) Water, Sodium Benzoate, Acrylates/Beheneth-25 Methacrylate Copolymer, Alginate, Caesalpinia Spinosa Gum, Glucomannan, Sodium Polyacrylate, Xanthan Gum, 1 ,4 Butandiol, Butylene Glycol, polyethylene glycol, Triethyl Citrate, Conjugated Linoleic Acid, Vegetable Oil, Passiflora Incarnata Seed Oil, Dicaprylyl Carbonate, Isononyl Isononanoate, Coco-Caprylate/Caprate, Dicaprylyl Ether, Caprylyl Caprylate/Caprate, Butyrospermum Parkii (Shea) Butter, Propylheptyl Caprylate, Undecane (and) Tridecane, Citric Acid, Hydrogenated Vegetable Glycerides, Sucrose Polystearate (and) Cetyl Palmitate, Sodium Stearoyl Glutamate, Octyldodecanol, Phenoxyethanol (and) Methylparaben, Polyglyceryl-3 Diisostearate, Cetearyl Alcohol, Ethylparaben (and) Propylene Glycol, Dipropylheptyl Carbonate, Glycerin (and) Myristyl Myristate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Cetearyl Alcohol (and) Potassium Cetyl Phosphate, Glycerin (and) Cetyl Palmitate (and) Ceteareth-12 (and) Glyceryl Stearate (and) Pentylene Glycol (and) Sodium Stearoyl Glutamate (and) Ceteareth-20 (and) Tetrahydroxypropyl Ethylenediamine (and) Cetearyl Alcohol (and) Water, Cetyl Ethylhexanoate, Ethylhexyl Palmitate, Triethylhexanoin, Cocoglycerides, Polyglyceryl-10 stearate, Polyglyceryl-10 Oleate, and Cetearyl Glucoside (and) Cetearyl Alcohol.
2. The use of a substance as a microbiome friendly ingredient in a cosmetic formulation, according to claim 1 , wherein this substance is selected from the group consisting of Ceteareth-12, Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, Disodium Cetearyl Sulfosuccinate, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate, Potassium Cetyl Phosphate, Sodium Cetearyl Sulfate and Laureth-7 Citrate.
3. The use of a substance as a microbiome friendly ingredient in a cosmetic formulation, according to claim 1, wherein this substance is selected from the group consisting of Cetearyl Alcohol (and) Lecithin (and) Sodium Cetearyl Sulfate (and) Olus Oil, Cetearyl Glucoside (and) Cetearyl Alcohol, ethyl linoleate, Glyceryl Oleate, Glyceryl Stearate (and) PEG-100 Stearate, Glyceryl Stearate Citrate, Lecithin, Polyglyceryl-2 Dipolyhydroxystearate and Potassium Cetyl Phosphate.
4. The use of a substance as a microbiome friendly ingredient in a cosmetic formulation, according to claim 1 , wherein this substance is selected from the group consisting of Glyceryl Stearate Citrate and Lecithin.
5. A cosmetic formulation having a composition identical to the composition of any of the following formulations or having a composition deviating from the composition of the following formulations in such a way that the amounts of the components of the cosmetic formulation deviate from the amounts of the components of the following formulations by +- 20 %, preferably +-10 %, more preferably by +- 5 %,
Formulation 1 : Formulation 2:
Formulation 3: Formulation 4:
Formulation 5:
Formulation 6:
Formulation 7: Formulation 8:
Formulation 9:
6. The non-therapeutic, cosmetic use of a formulation according to claim 5 as a microbiome friendly cosmetic formulation.
7. A method for cosmetically treating skin in a microbiome friendly way comprising contacting the skin with a formulation according to claim 5.
8. A formulation according to claim 5 for use in a method for treatment of the human or animal body by therapy, including prophylaxis.
9. A formulation according to claim 5 for use in a method for treating or preventing a disease caused by a disorder of the skin microbiome.
EP24715127.7A 2023-03-29 2024-03-25 Microbiome friendly substances and microbiome friendly cosmetic formulations Pending EP4687820A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023084714 2023-03-29
PCT/EP2024/057915 WO2024200338A1 (en) 2023-03-29 2024-03-25 Microbiome friendly substances and microbiome friendly cosmetic formulations

Publications (1)

Publication Number Publication Date
EP4687820A1 true EP4687820A1 (en) 2026-02-11

Family

ID=86054252

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24715127.7A Pending EP4687820A1 (en) 2023-03-29 2024-03-25 Microbiome friendly substances and microbiome friendly cosmetic formulations

Country Status (3)

Country Link
EP (1) EP4687820A1 (en)
CN (1) CN120936336A (en)
WO (1) WO2024200338A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006044618A1 (en) 2006-09-19 2008-03-27 Cognis Ip Management Gmbh Alkyl ether citrates for the selective cleansing of the skin
EP3970802A1 (en) 2020-09-22 2022-03-23 Beiersdorf AG Composition for promoting the skin microbiome

Also Published As

Publication number Publication date
WO2024200338A1 (en) 2024-10-03
CN120936336A (en) 2025-11-11

Similar Documents

Publication Publication Date Title
JP5224807B2 (en) Method for treating skin with Lactobacillus extract
KR102587334B1 (en) Strains for improving skin, and kit for improving skin using the same
JP2021529768A (en) Lactobacillus for skin care
JP6033435B2 (en) Antibacterial composition containing a phyllobasidium inhibitor derived from a natural product
US20180360712A1 (en) Cosmetic composition and use thereof
JPWO2009084200A1 (en) External skin preparation for acne skin
CN111265468A (en) Skin double-barrier repair composition and application thereof
JP6815006B2 (en) Acne strain selective antibacterial agent
CN115414308B (en) Acne-removing composition, preparation method and application
EP2255821A1 (en) Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics
KR102270709B1 (en) Cosmetic composition for skin improvement containing complex ceramide and natural extracts
CN114569536A (en) A lotion for improving microecology and physiological state of aged skin
WO2019029859A1 (en) COMPOSITION FOR THE CARE OF THE INTIMATE OR VAGINAL AREA
JP2023551278A (en) Methods and compositions for microbial treatment of skin disorders
KR102696095B1 (en) LACTOBACILLUS PLANTARUM Dr.G-001 ISOLATED FROM CITRUS NIPPOKOREANA, FERMENTED PRODUCT USING THE SAME AND COSMETIC COMPOSITION COMPRISING FERMENTED PRODUCT
EP1133979B1 (en) Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon
CN106420792A (en) Micro-nucleic acid acne-removing compound
EP1129694B1 (en) Use of components for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon
US20200046617A1 (en) Composition For Combating The Signs Of Ageing Of The Skin And Hair And Nails
FI131136B1 (en) Use of Nordic plant-based ingredients for supporting a healthy skin microbiome
US20240277782A1 (en) Compositions and methods for microbial treatment of skin disorders
EP0909557A1 (en) Use of honey as an agent for decreasing micro-organisms adhesion
KR20230131879A (en) Cosmetic method and composition based on short-chain fructooligosaccharides and natural starch
WO2024200338A1 (en) Microbiome friendly substances and microbiome friendly cosmetic formulations
US12161744B2 (en) Cordyceps containing topical skin care formulation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR